---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-090332"
form_type: "8-K"
ticker: "DSGN"
cik: "0001807120"
company_name: "Design Therapeutics, Inc."
filed_at: "2024-08-05T23:59:59+00:00"
generated_at: "2026-05-31T13:12:12.108906+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Design Therapeutics Q2 net loss $11.8M; cash $261M; FA and FECD programs on track

## Summary
- Net loss $11.8M for Q2 2024; R&D expense $10.5M, G&A expense $4.5M.
- Cash, cash equivalents and marketable securities $261.0M as of June 30; runway into 2029.
- FA program DT-216P2 on track to start patient trials in 2025 after GLP studies complete.
- FECD program DT-168 to begin Phase 1 in healthy volunteers in 2024; 200-patient observational study ongoing.

## SEC filing metadata
- accession: 0000950170-24-090332
- form_type: 8-K
- ticker: DSGN
- cik: 0001807120
- company_name: Design Therapeutics, Inc.
- filed_at: 2024-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1807120/000095017024090332/0000950170-24-090332-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1807120/000095017024090332/dsgn-20240805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-090332
- JSON: https://secwatch.observer/filing/0000950170-24-090332.json
- Plain text: https://secwatch.observer/filing/0000950170-24-090332.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.